Growth Metrics

Core Laboratories (CLB) Net Income towards Common Stockholders (2022 - 2026)

Core Laboratories filings provide 5 years of Net Income towards Common Stockholders readings, the most recent being -$704000.0 for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 1120.29% to -$704000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $29.6 million, a 2.84% increase, with the full-year FY2025 number at $30.4 million, down 5.48% from a year prior.
  • Net Income towards Common Stockholders hit -$704000.0 in Q1 2026 for Core Laboratories, down from $5.1 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $23.0 million in Q2 2023 to a low of -$704000.0 in Q1 2026.
  • Median Net Income towards Common Stockholders over the past 5 years was $7.3 million (2022), compared with a mean of $7.5 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: surged 220.99% in 2023 and later tumbled 1120.29% in 2026.
  • Core Laboratories' Net Income towards Common Stockholders stood at $6.0 million in 2022, then tumbled by 59.32% to $2.4 million in 2023, then skyrocketed by 208.59% to $7.5 million in 2024, then plummeted by 31.71% to $5.1 million in 2025, then tumbled by 113.73% to -$704000.0 in 2026.
  • The last three reported values for Net Income towards Common Stockholders were -$704000.0 (Q1 2026), $5.1 million (Q4 2025), and $14.5 million (Q3 2025) per Business Quant data.